MedPath

Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Phase 1
Terminated
Conditions
Brain and Central Nervous System Tumors
Liver Cancer
Ovarian Cancer
Kidney Cancer
Testicular Germ Cell Tumor
Childhood Germ Cell Tumor
Neuroblastoma
Unspecified Childhood Solid Tumor, Protocol Specific
Extragonadal Germ Cell Tumor
Lymphoma
Interventions
Drug: carboplatin
Drug: dasatinib
Drug: etoposide phosphate
Drug: ifosfamide
Genetic: microarray analysis
Genetic: western blotting
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: therapeutic conventional surgery
Radiation: radiation therapy
First Posted Date
2008-11-10
Last Posted Date
2023-07-14
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
7
Registration Number
NCT00788125
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Phase 2
Completed
Conditions
Stomach Cancer
Neoplasm of Cardioesophageal Junction
Gastric (Stomach) Cancer
Gastrointestinal Stromal Tumor (GIST)
Interventions
First Posted Date
2008-10-27
Last Posted Date
2021-07-01
Lead Sponsor
Pamela L. Kunz
Target Recruit Count
35
Registration Number
NCT00780494
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 2
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2008-10-09
Last Posted Date
2016-01-22
Lead Sponsor
Translational Oncology Research International
Target Recruit Count
18
Registration Number
NCT00769470
Locations
🇺🇸

Comprehensive Blood and Cancer Center, Bakersfield, California, United States

🇺🇸

St. Jude Heritage Medical Group at Virginia K. Crosson Cancer Center, Fullerton, California, United States

🇺🇸

Sansum Medical Clinic, Santa Barbara, California, United States

and more 12 locations

A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

Phase 2
Withdrawn
Conditions
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Interventions
First Posted Date
2008-10-07
Last Posted Date
2015-10-28
Lead Sponsor
Eli Lilly and Company
Registration Number
NCT00768131
Locations
🇺🇸

Local Institution, Austin, Texas, United States

Phase II Avastin Trial for Stage IIIB/IV NSCLC

Phase 2
Terminated
Conditions
Non-small Cell Lung Cancer Stage IIIB
Non-small Cell Lung Cancer Stage IV
Interventions
First Posted Date
2008-10-03
Last Posted Date
2016-04-19
Lead Sponsor
Pharmatech
Target Recruit Count
125
Registration Number
NCT00766246

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

Phase 3
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
First Posted Date
2008-09-30
Last Posted Date
2015-12-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
939
Registration Number
NCT00762034
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States

Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma

Phase 2
Terminated
Conditions
Ovarian Cancer
Interventions
First Posted Date
2008-09-25
Last Posted Date
2015-09-28
Lead Sponsor
Hellenic Oncology Research Group
Target Recruit Count
34
Registration Number
NCT00758732
Locations
🇬🇷

University Hospital of Crete, Heraklion, Crete, Greece

🇬🇷

"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece

🇬🇷

Department of Medical Oncology, "Marika Iliadis" Hospital of Athens, Athens, Greece

and more 9 locations

Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

Phase 1
Completed
Conditions
Cancer
Non-Small Cell Lung Cancer
Endometrial Carcinoma
Ovarian Carcinoma
Interventions
Drug: XL147 (SAR245408),
Drug: paclitaxel
Drug: carboplatin
First Posted Date
2008-09-22
Last Posted Date
2013-04-10
Lead Sponsor
Sanofi
Target Recruit Count
52
Registration Number
NCT00756847
Locations
🇺🇸

Investigational Site Number, Madison, Wisconsin, United States

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

Completed
Conditions
Chemotherapeutic Agent Toxicity
Cognitive/Functional Effects
Psychosocial Effects of Cancer and Its Treatment
Fatigue
Long-term Effects Secondary to Cancer Therapy in Adults
Breast Cancer
Neurotoxicity
First Posted Date
2008-09-18
Last Posted Date
2017-11-24
Lead Sponsor
University of California, San Francisco
Target Recruit Count
81
Registration Number
NCT00755313
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath